Technical Analysis for TCON - TRACON Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.795 16.91% 0.12
TCON closed up 16.91 percent on Friday, May 17, 2019, on 2.36 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical TCON trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
New Uptrend Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Wide Range Bar Range Expansion 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish 16.91%

Older signals for TCON ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The company is planning for clinical trials of TRC105, including a Phase II clinical trial in patients with breast cancer and hepatocellular carcinoma, a Phase I clinical trial in patients with colorectal cancer, and a Phase I clinical trial in patients with lung cancer, as well as conducting preclinical studies of TRC105 in AMD. In addition, the company product candidates comprise TRC205, an anti-endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Medicine Health Biopharmaceutical Cancer Drugs Clinical Trial Breast Cancer Colorectal Cancer Glioblastoma Age Related Macular Degeneration Targeted Therapy Hepatocellular Carcinoma Lung Cancer Renal Cell Carcinoma Therapeutics For Cancer Fibrotic Diseases Ros1 Transgene Sa
Is TCON a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 3.2
52 Week Low 0.5
Average Volume 426,290
200-Day Moving Average 1.3644
50-Day Moving Average 1.0506
20-Day Moving Average 0.6797
10-Day Moving Average 0.6984
Average True Range 0.0818
ADX 32.9
+DI 25.7075
-DI 23.2704
Chandelier Exit (Long, 3 ATRs ) 0.6046
Chandelier Exit (Short, 3 ATRs ) 0.8754
Upper Bollinger Band 0.746
Lower Bollinger Band 0.6134
Percent B (%b) 1.37
BandWidth 19.508607
MACD Line -0.0798
MACD Signal Line -0.1115
MACD Histogram 0.0316
Fundamentals Value
Market Cap 13.24 Million
Num Shares 16.7 Million
EPS -1.75
Price-to-Earnings (P/E) Ratio -0.45
Price-to-Sales 17.03
Price-to-Book 2.65
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.09
Resistance 3 (R3) 1.08 0.96 1.04
Resistance 2 (R2) 0.96 0.89 0.97 1.03
Resistance 1 (R1) 0.88 0.84 0.92 0.89 1.01
Pivot Point 0.77 0.77 0.79 0.77 0.77
Support 1 (S1) 0.68 0.69 0.72 0.70 0.58
Support 2 (S2) 0.57 0.64 0.57 0.56
Support 3 (S3) 0.48 0.57 0.55
Support 4 (S4) 0.50